Immuthera

Executive Summary

Immuthera is a Warsaw-based biotechnology company pioneering first-in-class cell therapies for autoimmune diseases. Its proprietary platform, CoRe-T cells, are CD6/CTLA-4 CAR-Tregs engineered to specifically suppress autoreactive T-cells while preserving normal immune function. The company is initially targeting Type 1 Diabetes, dermatological conditions, and neuroinflammatory indications. Having recently advanced to Phase 1 clinical development, Immuthera represents an early-stage opportunity with a novel approach to addressing a large unmet need in autoimmune disease. The platform's dual-targeting mechanism may provide enhanced specificity and reduced off-target effects compared to conventional CAR-Treg therapies. As a private company with limited public data, the risk profile is elevated, but the potential for disease-modifying therapy in chronic autoimmune conditions is significant. Key upcoming catalysts include initial Phase 1 safety and efficacy data, potential partnership or licensing deals to expand pipeline, and IND/CTA approvals for additional indications.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 safety data readout for lead indication (Type 1 Diabetes)40% success
• Q2 2027Regulatory approval for Phase 2 trial design in dermatological indication60% success
• H1 2027Strategic partnership or licensing deal for CoRe-T platform30% success